Atea Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
MA
Business Address
225 FRANKLIN STREET, BOSTON, MA, 02110
Mailing Address
225 FRANKLIN STREET, BOSTON, MA, 02110
Phone
(857) 284-8891
Fiscal Year End
1231
EIN
460574869
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- AT-527 (COVID-19) successfully completed Phase 2 and is set for Phase 3 initiation in early 2026.
- Strong cash position of $310.5 million with a projected runway into the second half of 2027, operating debt-free.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.